Harrow Launches BYOOVIZ, FDA-Approved Biosimilar for Retinal Diseases

Harrow, Inc. announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar developed by Samsung Bioepis. This launch follows an exclusive U.S. commercialization agreement, positioning BYOOVIZ as the first ophthalmology biosimilar in the U.S. for conditions like Wet Age-Related Macular Degeneration. The product is an interchangeable biosimilar to LUCENTIS® and is expected to significantly strengthen Harrow's retina franchise in the estimated $9 billion U.S. anti-VEGF market, alongside its existing products IHEEZO® and TRIESENCE®.